Advertisement

Pharmacy World and Science

, Volume 28, Issue 1, pp 26–32 | Cite as

Regional Influences on the Dispensing of Glucose Test Strips in Dutch Community Pharmacies

  • Michiel J. Storimans
  • Olaf H. KlungelEmail author
  • Herre Talsma
  • Cornelis J. de Blaey
Article

Abstract

Background: Pharmacy practice guidelines promote the role of community pharmacies in self-monitoring of blood glucose. However, variations between Dutch pharmacies exist in the proportion of patients to whom test strips are dispensed. Objective: To assess whether variations between community pharmacies in dispensing of blood glucose test strips can be explained by differences in patient characteristics and the region in which the pharmacy is located. Setting: PHARMO-Record Linkage System containing drug dispensing histories from 40 community pharmacies of about 450,000 patients in the Netherlands. Method: We performed a retrospective cohort study. Data on prescription of all drugs and medical aids between 1991 and 2001 were extracted for all new users of antidiabetic drugs. Patients were excluded if the dispensing history did not allow classification of the type of diabetes or if the dispensing pharmacy could not be determined. The data were analysed using a Cox proportional hazard model. Main outcome measure: Time to first test strips dispensed. Results: We identified 8,233 starters of antidiabetic drugs. During a median follow-up of 2.1 years, 20% of the patients were dispensed test strips at least once. Community pharmacy was significantly associated with the dispensing of test strips after adjustment for patient characteristics. This association was less apparent when stratified for the geographical location of the pharmacy. Conclusion: Community pharmacy is an independent determinant of the start of use of test strips. Differences in dispensing of test strips between pharmacies are dependent on geographical region. This suggests that implementing practice guidelines for diabetes care in community pharmacy requires different approaches in different regions.

Key words

Cohort analysis Diabetes mellitus  Blood glucose monitoring Pharmaceutical care  Netherlands Glucose test strips 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

This study was supported by an unrestricted grant from the Royal Society for the Advancement of Pharmacy (KNMP), the Hague, the Netherlands.

References

  1. 1.
    Stratton IM (2000). Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405–412CrossRefPubMedGoogle Scholar
  2. 2.
    The DCCT Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications insulin-dependent diabetes mellitus. NEJM 329: 977–986CrossRefGoogle Scholar
  3. 3.
    American Diabetes Association (2004). Standards of medical care in diabetes. Diab Care 27: S15–S35CrossRefGoogle Scholar
  4. 4.
    Wiersma TJ, Heine RJ and Rutten GHE (2006). NHG–Standard Diabetes mellitus type 2: Tweede herziening. Huisarts Wet 49: 137–152Google Scholar
  5. 5.
    American Diaberes Association (2004). Tests of glycemia in diabetes. Diab Care 27: S91–S93CrossRefGoogle Scholar
  6. 6.
    EuroPharmForum (2001) Improved quality in diabetes care: the pharmacist in St Vincent team: protocol and guidelines. http://www.euro.who.int/document/e75680.pdf (6 Jun. 2005)
  7. 7.
    Practice Guidance for Community Pharmacists on the Care of People with Diabetes. London: Royal Pharmaceutical Society of Great Britain. Nov 2004. http://www.rpsgb.org/pdfs/diabguid3.pdf#xml=http://www.rpsgb.org/search/pdfhi.php? all=l&filepath=../pdfs/diabguid3.pdf&search= diabetes (6 Jun. 2005)
  8. 8.
    American Society of Hospital Pharmacists (ASHP) (1995) Therapeutic position statement on strict glycemic control in selected patients with insulin-dependent diabetes mellitus. Am J Health-Syst Pharm 52: 2709–2711Google Scholar
  9. 9.
    WINAp (2000) FPZ Standaard Diabetes Mellitus Type 2 [Pharmaceutical Care Standard Diabetes Mellitus Type 2]. Den Haag: WINApGoogle Scholar
  10. 10.
    Storimans MJ, Talsma H and Klungel OH (2004). Dispensing glucose test materials in Dutch community pharmacies. Pharm World Sci 32: 52–55CrossRefGoogle Scholar
  11. 11.
    Scorpiglione N (1996). Epidemiology and determinants of blood glucose self-monitoring in clinical practice. Diabetes Res Clin Pract 34: 115–125CrossRefPubMedGoogle Scholar
  12. 12.
    Karter AJ, Ferrara A, Darbinian JA, Ackerson LM and Selby JV (2000). Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. Diab care 23: 477–483CrossRefGoogle Scholar
  13. 13.
    Arday DR, Fleming BB and Keller DK (2002). Variation in diabetes care among states: do patient characteristics matter?. Diab Care 25: 2230–2237CrossRefGoogle Scholar
  14. 14.
    Herings R, Stricker B, Boer Ade, Bakker A and Sturmans F (1995). Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 155: 1801–1807CrossRefPubMedGoogle Scholar
  15. 15.
    Herings R, Stricker B, Boer Ade, Leufkens H and Porsius A (1995). Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 345: 1195–1198CrossRefPubMedGoogle Scholar
  16. 16.
    Erkens JA (2001). Cardiovascular drug use and hospitalisations attributable to type 2 diabetes mellitus. Diab Care 24: 1428–1432CrossRefGoogle Scholar
  17. 17.
    Zgibor JC and Simmons D (2002). Barriers to blood glucose monitoring in a multiethnic community. Diab Care 25: 1772–1777CrossRefGoogle Scholar
  18. 18.
    Harris MI, Cowie CC and Howie LJ (1993). Self-monitoring of blood glucose by adults with diabetes in the United States population. Diab care 16: 1116–1123CrossRefGoogle Scholar
  19. 19.
    O’Connor GT (1999). Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA 281: 627–633CrossRefPubMedGoogle Scholar
  20. 20.
    Skinner J, Weinstein JN, Sporer SM and Wennberg JE (2003). Racial, ethnic, and geographic disparities in rates of knee arthroplasty among medicare patients. New Eng J Med 349: 1350–1359CrossRefPubMedGoogle Scholar
  21. 21.
    Wennberg JE (1999). Understanding geographic variations in health care delivery. New Eng J Med 340: 52–53CrossRefPubMedGoogle Scholar
  22. 22.
    Bell HM, McElnay JC and Hughes CM (1998). A qualitative investigation of the attitudes and opinions of community pharmacists to pharmaceutical care. J Soc Adm Pharm 15: 284–295Google Scholar
  23. 23.
    Odedina FT, Segal R and Hepler CD (1995). Providing pharmaceutical care in community practice: differences between providers and non-providers of pharmaceutical care. J Soc Adm Pharm 12: 170–180Google Scholar
  24. 24.
    Stichting Farmaceutische Kengetallen (2001) Farmacie in cijfers: toename in gebruik hulpmiddelen [Pharmacy in figures: rise in use of medical aids]. Pharm Weekbl 136: 829Google Scholar
  25. 25.
    Lutterman J (2002) Farmacotherapie bij diabetes mellitus: huidige situatie en toekomstverwachtingen [Pharmocotherapy of diabetes mellitus: current situation and projections]. In: Timmerman H, van den Bery Jeths A, editors. Volksgezondheid toekomst verkenningen. Bilthoven: RIVM. ISBN 90-313-3702-1Google Scholar
  26. 26.
    Cranor CW, Bunting BA and Christensen DB (2003). The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash) 43: 173–184CrossRefGoogle Scholar
  27. 27.
    Cranor CW and Christensen DB (2003). The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash) 43: 149–159CrossRefGoogle Scholar
  28. 28.
    Berringer R et al. Outcomes of a community pharmacy-based diabetes monitoring program. J Am Pharm Assoc (Wash) 1999; 39: 791–797Google Scholar
  29. 29.
    Cioffi ST, Caron MF, Kalus JS, Hill P, Buckley TE. Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic. 2004; 38: 771–775Google Scholar
  30. 30.
    Wermeille J, Bennie M, Brown I, McKnight J. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team – a pilot study. Pharm World Sci 2004; 26: 18–25Google Scholar
  31. 31.
    Stichting Farmaceutische Kengetallen (2003) Weer meer apotheken [Again, more pharmacies]. Pharm Weekbl 138: 128Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Michiel J. Storimans
    • 1
    • 2
  • Olaf H. Klungel
    • 1
    Email author
  • Herre Talsma
    • 1
  • Cornelis J. de Blaey
    • 1
    • 2
  1. 1.Department of Pharmacoepidemiology and pharmacotherapy, Utrecht Institute for Pharmaceutical SciencesUtrecht UniversityUtrechtThe Netherlands
  2. 2.Scientific Institute Dutch PharmacistsThe HagueThe Netherlands

Personalised recommendations